Status:
COMPLETED
Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer
Lead Sponsor:
Hospital San Juan de Dios, Santiago
Conditions:
Cisplatin Adverse Reaction
Hearing Loss Ototoxic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can cause a lot of deterioration in patients. Early diagnosis is essential because it would allow the appropri...
Eligibility Criteria
Inclusion
- Adults Patients with Head and Neck Squamous Cell carcinoma requiring Chemoradiotherapy including Cisplatin.
Exclusion
- Conductive Hearing Loss
- SNHL with \>= 40db PTA
Key Trial Info
Start Date :
November 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03400709
Start Date
November 1 2015
End Date
November 1 2017
Last Update
January 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daniel Munoz
Santiago, Santiago Metropolitan, Chile, 7160166